Peter Kolchinsky portfolio, Q3 2024
RA Capital Management · 13F for the quarter ending Sep 30, 2024
For Q3 2024, RA Capital Management reported $8.7B across 81 US-listed positions, led by ASND (16.7%), PCVX (11.4%) and JANX (4.8%). Compared with its filing for Q2 2024, Peter Kolchinsky opened 9 new positions, added to 9, reduced 14 and sold out of 6; 49 positions did not change.
The largest purchase was a new position in BCAX ($177.2M); the largest sale, the sale of the whole position in Longboard Pharmaceuticals ($88.9M).
Key facts
- 13F portfolio value
- $8.7BQ3 2024
- Positions
- 81
- Largest holding
- ASND 16.7%
- New positions
- 9
- Sold out
- 6
- Filed
- Nov 14, 2024
Holdings as of (Q3 2024), filed with the SEC on . Changes are measured against the filing for Jun 30, 2024. Every tracked investor's Q3 2024 13F.
Bought and sold in Q3 2024
| Stock | Move | Shares | Size | Of portfolio |
|---|---|---|---|---|
| Bicara Therapeutics IncBCAX | ▲ New | +6.96M | $177.2M | 2.04% |
| Artiva Biotherapeutics IncARTV | ▲ New | +9.85M | $152.2M | 1.76% |
Longboard Pharmaceuticalsno ticker on file | ▼ Sold out | −3.29M | $88.9M | 1.03% |
Verona Pharma Plcno ticker on file | ▼ Reduced 34% | −2.62M | $75.5M | 0.87% |
| Geron CorpGERN | ▼ Reduced 30% | −13.92M | $63.2M | 0.73% |
| Ascendis Pharma A/SASND | ▼ Reduced 3.9% | −397.97K | $59.4M | 0.69% |
| Vaxcyte IncPCVX | ▲ Added 5.9% | +485.44K | $55.5M | 0.64% |
| UroGen Pharma LtdURGN | ▼ Sold out | −3.08M | $51.7M | 0.60% |
| Bioage Labs IncBIOA | ▲ New | +2.21M | $46M | 0.53% |
| IDEAYA Biosciences IncIDYA | ▲ New | +1.35M | $42.7M | 0.49% |
Avidity Biosciences Incno ticker on file | ▲ Added 17% | +900K | $41.3M | 0.48% |
| MBX Biosciences IncMBX | ▲ New | +1.51M | $39.3M | 0.45% |
| Biogen IncBIIB | ▲ Added 21% | +202.32K | $39.2M | 0.45% |
| Praxis Precision MedicinesPRAX | ▼ Reduced 38% | −473.64K | $27.3M | 0.31% |
| Enliven Therapeutics IncELVN | ▼ Reduced 50% | −1.06M | $27.1M | 0.31% |
Arcellx Incno ticker on file | ▲ Added 15% | +247.47K | $20.7M | 0.24% |
| Nurix Therapeutics IncNRIX | ▼ Sold out | −650K | $13.6M | 0.16% |
Cybin Incno ticker on file | ▼ Sold out | −44M | $11.9M | 0.14% |
| Dyne Therapeutics IncDYN | ▲ Added 5.5% | +331.94K | $11.9M | 0.14% |
| Xencor IncXNCR | ▲ New | +575K | $11.6M | 0.13% |
| RxSight IncRXST | ▲ Added 6.0% | +222K | $11M | 0.13% |
Third Harmonic Bio Incno ticker on file | ▼ Reduced 37% | −752.23K | $10.2M | 0.12% |
| Avalo Therapeutics IncAVTX | ▲ New | +967K | $9.2M | 0.11% |
| Macrogenics IncMGNX | ▼ Sold out | −2.08M | $8.8M | 0.10% |
Regulus Therapeutics Incno ticker on file | ▼ Reduced 88% | −5.48M | $8.6M | 0.10% |
Cidara Therapeutics Incno ticker on file | ▲ New | +703.08K | $7.6M | 0.09% |
Nuvalent Incno ticker on file | ▲ Added 47% | +56.49K | $5.8M | 0.07% |
| Fulcrum Therapeutics IncFULC | ▼ Reduced 12% | −1.38M | $4.9M | 0.06% |
| AN2 Therapeutics IncANTX | ▼ Reduced 64% | −3.55M | $3.8M | 0.04% |
| Adagio Medical Holdings IncADGM | ▲ New | +1.33M | $3.4M | 0.04% |
Iteos Therapeutics Incno ticker on file | ▼ Reduced 9.5% | −332.55K | $3.4M | 0.04% |
| Unicycive Therapeutics IncUNCY | ▼ Sold out | −2.63M | $1.3M | 0.02% |
| Tenaya Therapeutics IncTNYA | ▼ Reduced 8.4% | −639.76K | $1.2M | 0.01% |
| Lexeo Therapeutics IncLXEO | ▼ Reduced 19% | −126.16K | $1.1M | 0.01% |
Astria Therapeutics Incno ticker on file | ▲ Added 1.2% | +61.46K | $676.6K | 0.01% |
| GH Research PLCGHRS | ▲ Added 1.3% | +85K | $568.6K | 0.01% |
| Metagenomi IncMGX | ▼ Reduced 12% | −172.51K | $374.3K | 0.00% |
| Alto Neuroscience IncANRO | ▼ Reduced 0.5% | −10.4K | $119K | 0.00% |
Holdings at the quarter's end
| # | Stock | Sector | Share of portfolio | Value | Shares | Reported price | Held | Since Q2 2024 |
|---|---|---|---|---|---|---|---|---|
| 1 | Ascendis Pharma A/SASND · SPONSORED ADR | Health Care | 16.7% | $1.4B | 9.71M | $149.31 | 2+ qtrs | ▼ Reduced 3.9% |
| 2 | Vaxcyte IncPCVX | Health Care | 11.4% | $992.9M | 8.69M | $114.27 | 2+ qtrs | ▲ Added 5.9% |
| 3 | Janux Therapeutics IncJANX | — | 4.80% | $416.4M | 9.17M | $45.43 | 2+ qtrs | No change |
| 4 | Legend Biotech CorpLEGN · SH | Health Care | 4.22% | $365.8M | 7.51M | $48.73 | 2+ qtrs | No change |
| 5 | Rhythm Pharmaceuticals IncRYTM | Health Care | 3.68% | $318.8M | 6.08M | $52.39 | 2+ qtrs | No change |
| 6 | Avidity Biosciences Incno ticker on file · SH | — | 3.34% | $289.4M | 6.3M | $45.93 | 2+ qtrs | ▲ Added 17% |
| 7 | Tyra Biosciences IncTYRA | — | 2.82% | $244.9M | 10.42M | $23.51 | 2+ qtrs | No change |
| 8 | Evolent Health IncEVH · SH | — | 2.78% | $240.8M | 8.51M | $28.28 | 2+ qtrs | No change |
| 9 | Edgewise Therapeutics IncEWTX | Health Care | 2.74% | $237.8M | 8.91M | $26.69 | 2+ qtrs | No change |
| 10 | Biogen IncBIIB · SH | Health Care | 2.65% | $229.6M | 1.18M | $193.84 | 2+ qtrs | ▲ Added 21% |
| 11 | Dyne Therapeutics IncDYN · SH | — | 2.64% | $229.2M | 6.38M | $35.92 | 2+ qtrs | ▲ Added 5.5% |
| 12 | RxSight IncRXST · SH | — | 2.23% | $193.6M | 3.92M | $49.43 | 2+ qtrs | ▲ Added 6.0% |
| 13 | Bicara Therapeutics IncBCAX | — | 2.04% | $177.2M | 6.96M | $25.47 | 1 qtr | New |
| 14 | Climb Bio IncCLYM | — | 1.84% | $159.9M | 31.42M | $5.09 | 2+ qtrs | No change |
| 15 | Ars Pharmaceuticals IncSPRY | — | 1.82% | $157.5M | 10.86M | $14.50 | 2+ qtrs | No change |
| 16 | Arcellx Incno ticker on file · SH | — | 1.78% | $154.6M | 1.85M | $83.51 | 2+ qtrs | ▲ Added 15% |
| 17 | Artiva Biotherapeutics IncARTV | — | 1.76% | $152.2M | 9.85M | $15.45 | 1 qtr | New |
| 18 | Wave Life Sciences LtdWVE | — | 1.72% | $149.3M | 18.2M | $8.20 | 2+ qtrs | No change |
| 19 | Geron CorpGERN | — | 1.69% | $146.6M | 32.29M | $4.54 | 2+ qtrs | ▼ Reduced 30% |
| 20 | Verona Pharma Plcno ticker on file · SH | — | 1.66% | $144.1M | 5.01M | $28.77 | 2+ qtrs | ▼ Reduced 34% |
| 21 | Newamsterdam Pharma CompanyNAMS | — | 1.54% | $133.9M | 8.06M | $16.60 | 2+ qtrs | No change |
| 22 | Apogee Therapeutics Incno ticker on file · SH | — | 1.33% | $115.2M | 1.96M | $58.74 | 2+ qtrs | No change |
| 23 | Day One Biopharmaceuticalsno ticker on file · SH | — | 1.26% | $109.7M | 7.87M | $13.93 | 2+ qtrs | No change |
| 24 | 89BIO Incno ticker on file · SH | — | 1.21% | $104.9M | 14.18M | $7.40 | 2+ qtrs | No change |
| 25 | Recursion Pharmaceuticals IncRXRX · SH | — | 1.17% | $101.4M | 15.38M | $6.59 | 2+ qtrs | No change |
| 26 | Lenz Therapeutics IncLENZ | — | 1.14% | $99.2M | 4.18M | $23.74 | 2+ qtrs | No change |
| 27 | Pepgen IncPEPG | — | 1.05% | $91.4M | 10.69M | $8.55 | 2+ qtrs | No change |
| 28 | Axsome Therapeutics IncAXSM · SH | Health Care | 1.04% | $89.9M | 1M | $89.87 | 2+ qtrs | No change |
| 29 | Structure Therapeutics IncGPCR · SH | — | 0.96% | $83.2M | 1.9M | $43.89 | 2+ qtrs | No change |
| 30 | Tourmaline Bio Incno ticker on file · SH | — | 0.75% | $65.3M | 2.54M | $25.71 | 2+ qtrs | No change |
| 31 | Dianthus Therapeutics IncDNTH | Health Care | 0.74% | $63.9M | 2.33M | $27.38 | 2+ qtrs | No change |
| 32 | Mineralys Therapeutics IncMLYS | — | 0.68% | $58.7M | 4.85M | $12.11 | 2+ qtrs | No change |
| 33 | Acrivon Therapeutics IncACRV | — | 0.67% | $58.4M | 8.34M | $7.00 | 2+ qtrs | No change |
| 34 | Astria Therapeutics Incno ticker on file · SH | — | 0.65% | $56.2M | 5.11M | $11.01 | 2+ qtrs | ▲ Added 1.2% |
| 35 | 4D Molecular TherapeuticsFDMT | — | 0.64% | $55.1M | 5.1M | $10.81 | 2+ qtrs | No change |
| 36 | CG Oncology IncCGON · SH | Health Care | 0.61% | $52.7M | 1.4M | $37.73 | 2+ qtrs | No change |
| 37 | Bicycle Therapeutics PlcBCYC · SH | — | 0.59% | $51M | 2.25M | $22.63 | 2+ qtrs | No change |
| 38 | Nkarta IncNKTX | — | 0.56% | $48.8M | 10.81M | $4.52 | 2+ qtrs | No change |
| 39 | Bioage Labs IncBIOA | — | 0.53% | $46M | 2.21M | $20.80 | 1 qtr | New |
| 40 | GH Research PLCGHRS | — | 0.52% | $44.7M | 6.69M | $6.69 | 2+ qtrs | ▲ Added 1.3% |
| 41 | Praxis Precision MedicinesPRAX | Health Care | 0.51% | $43.8M | 761.96K | $57.54 | 2+ qtrs | ▼ Reduced 38% |
| 42 | IDEAYA Biosciences IncIDYA · SH | — | 0.49% | $42.7M | 1.35M | $31.68 | 1 qtr | New |
| 43 | Larimar Therapeutics IncLRMR · SH | — | 0.46% | $39.6M | 6.05M | $6.55 | 2+ qtrs | No change |
| 44 | MBX Biosciences IncMBX · SH | — | 0.45% | $39.3M | 1.51M | $25.98 | 1 qtr | New |
| 45 | Acumen Pharmaceuticals IncABOS | — | 0.43% | $37M | 14.93M | $2.48 | 2+ qtrs | No change |
| 46 | Fulcrum Therapeutics IncFULC | — | 0.42% | $36.5M | 10.23M | $3.57 | 2+ qtrs | ▼ Reduced 12% |
| 47 | Iteos Therapeutics Incno ticker on file · SH | — | 0.38% | $32.5M | 3.18M | $10.21 | 2+ qtrs | ▼ Reduced 9.5% |
| 48 | Solid Biosciences IncSLDB | — | 0.35% | $30.2M | 4.33M | $6.97 | 2+ qtrs | No change |
| 49 | C4 Therapeutics IncCCCC | — | 0.32% | $27.8M | 4.88M | $5.70 | 2+ qtrs | No change |
| 50 | Enliven Therapeutics IncELVN · SH | — | 0.31% | $27.1M | 1.06M | $25.54 | 2+ qtrs | ▼ Reduced 50% |
| 51 | Alto Neuroscience IncANRO · SH | — | 0.27% | $23.7M | 2.08M | $11.44 | 2+ qtrs | ▼ Reduced 0.5% |
| 52 | Sera Prognostics IncSERA · SH | — | 0.27% | $23.7M | 3.03M | $7.80 | 2+ qtrs | No change |
| 53 | Taysha Gene Therapies IncTSHA | — | 0.25% | $21.9M | 10.87M | $2.01 | 2+ qtrs | No change |
| 54 | Immatics N.V.IMTX · SH | — | 0.23% | $20M | 1.75M | $11.41 | 2+ qtrs | No change |
| 55 | Aerovate Therapeutics Incno ticker on file · SH | — | 0.22% | $19.2M | 9.19M | $2.09 | 2+ qtrs | No change |
| 56 | Nuvalent Incno ticker on file | — | 0.21% | $18M | 176.28K | $102.30 | 2+ qtrs | ▲ Added 47% |
| 57 | Third Harmonic Bio Incno ticker on file · SH | — | 0.20% | $17.4M | 1.28M | $13.55 | 2+ qtrs | ▼ Reduced 37% |
| 58 | Vor Biopharma IncVOR · SH | — | 0.18% | $15.9M | 22.75M | $0.7000 | 2+ qtrs | No change |
| 59 | Insmed IncINSM · SH | Health Care | 0.17% | $14.6M | 200K | $73.00 | 2+ qtrs | No change |
| 60 | Pliant Therapeutics IncPLRX · SH | — | 0.17% | $14.4M | 1.28M | $11.21 | 2+ qtrs | No change |
| 61 | Tenaya Therapeutics IncTNYA · SH | — | 0.16% | $13.5M | 6.98M | $1.93 | 2+ qtrs | ▼ Reduced 8.4% |
| 62 | Zura Bio LtdZURA · SH | — | 0.15% | $13.1M | 3.22M | $4.06 | 2+ qtrs | No change |
| 63 | Werewolf Therapeutics IncHOWL | — | 0.15% | $13M | 6.14M | $2.12 | 2+ qtrs | No change |
| 64 | Cervomed IncCRVO · SH | — | 0.14% | $11.9M | 817.12K | $14.60 | 2+ qtrs | No change |
| 65 | Xencor IncXNCR | — | 0.13% | $11.6M | 575K | $20.11 | 1 qtr | New |
| 66 | Adicet Bio IncACET · SH | — | 0.13% | $10.9M | 7.54M | $1.44 | 2+ qtrs | No change |
| 67 | Arvinas IncARVN · SH | — | 0.12% | $10.4M | 421.35K | $24.63 | 2+ qtrs | No change |
| 68 | Avalo Therapeutics IncAVTX | — | 0.11% | $9.2M | 967K | $9.50 | 1 qtr | New |
| 69 | Chimerix Incno ticker on file · SH | — | 0.09% | $8.2M | 8.8M | $0.9300 | 2+ qtrs | No change |
| 70 | Boundless Bio IncBOLD · SH | — | 0.09% | $7.6M | 2.18M | $3.47 | 2+ qtrs | No change |
| 71 | Cidara Therapeutics Incno ticker on file · SH | — | 0.09% | $7.6M | 703.08K | $10.75 | 1 qtr | New |
| 72 | Perceptive Cap Solutionsno ticker on file | — | 0.09% | $7.5M | 750K | $10.02 | 2+ qtrs | No change |
| 73 | Lexeo Therapeutics IncLXEO | — | 0.06% | $4.9M | 546.55K | $9.04 | 2+ qtrs | ▼ Reduced 19% |
| 74 | Protara Therapeutics IncTARA · SH | — | 0.04% | $3.5M | 1.9M | $1.83 | 2+ qtrs | No change |
| 75 | Adagio Medical Holdings IncADGM · SH | — | 0.04% | $3.4M | 1.33M | $2.58 | 1 qtr | New |
| 76 | Surrozen IncSRZN · SH | — | 0.04% | $3.4M | 282.58K | $11.98 | 2+ qtrs | No change |
| 77 | Metagenomi IncMGX · SH | — | 0.03% | $2.8M | 1.31M | $2.17 | 2+ qtrs | ▼ Reduced 12% |
| 78 | Newamsterdam Pharma Co NV-27no ticker on file · WTS | — | 0.03% | $2.3M | 333.33K | $7.00 | 2+ qtrs | No change |
| 79 | AN2 Therapeutics IncANTX · SH | — | 0.03% | $2.1M | 2M | $1.07 | 2+ qtrs | ▼ Reduced 64% |
| 80 | Regulus Therapeutics Incno ticker on file · SH | — | 0.01% | $1.2M | 766.83K | $1.57 | 2+ qtrs | ▼ Reduced 88% |
| 81 | Scilex Holding Cono ticker on file · SH | — | 0.00% | $241.5K | 261.18K | $0.9246 | 2+ qtrs | No change |
By sector
| Sector | Share of portfolio | Value | Positions |
|---|---|---|---|
| Health Care | 44.5% | $3.9B | 11 |
| No sector on file | 55.5% | $4.8B | 70 |
Questions and answers
What did Peter Kolchinsky own in Q3 2024?
RA Capital Management's 13F for Q3 2024 lists 81 positions worth $8.7B. The largest: ASND (16.7%), PCVX (11.4%), JANX (4.8%), LEGN (4.2%), RYTM (3.7%).
What did Peter Kolchinsky buy in Q3 2024?
The largest purchases, by the shares bought at the quarter-end price the filing implies: BCAX (new, $177.2M), ARTV (new, $152.2M), PCVX (added, $55.5M), BIOA (new, $46M), IDYA (new, $42.7M), Avidity Biosciences Inc (added, $41.3M).
What did Peter Kolchinsky sell in Q3 2024?
The largest sales: Longboard Pharmaceuticals (sold out, $88.9M), Verona Pharma Plc (reduced, $75.5M), GERN (reduced, $63.2M), ASND (reduced, $59.4M), URGN (sold out, $51.7M), PRAX (reduced, $27.3M).
When was this filing made?
RA Capital Management filed its 13F for the quarter ending Sep 30, 2024 on Nov 14, 2024. A 13F is due within 45 days of the quarter's end, so the positions were already weeks old when it became public.
Learn
Cite this page
Funkfolio, “Peter Kolchinsky portfolio, Q3 2024: RA Capital Management 13F holdings”, data as of 14 November 2024. https://funkfolio.com/gurus/peter-kolchinsky/2024-q3
Underlying data: SEC EDGAR, Form 13F-HR of RA Capital Management (CIK 1346824) for the period ending Sep 30, 2024.
Source: SEC EDGAR, Form 13F-HR for RA Capital Management (CIK 1346824), period ending Sep 30, 2024, filed Nov 14, 2024. Changes compare share counts with the filing for Jun 30, 2024; a share split in between is allowed for where one is on record. “Reported price” is a position's reported value divided by its shares. The size of a buy or sell is the change in shares at that price; a position sold out is sized at its value in the previous filing, and “of portfolio” sets the size against the $8.7B reported for this quarter. “Held” counts consecutive quarterly filings up to this one, out of the 2 looked at from here back. Sectors are those of the ranked companies on this site as they stand today. Not a live portfolio and not advice.